

Cell-based therapy for hypoxic-ischemic injury in the preterm brain

Citation for published version (APA):

Jellema, R. K. (2014). *Cell-based therapy for hypoxic-ischemic injury in the preterm brain*. [Doctoral Thesis, Maastricht University]. Datawyse / Universitaire Pers Maastricht. <https://doi.org/10.26481/dis.20140923rj>

Document status and date:

Published: 01/01/2014

DOI:

[10.26481/dis.20140923rj](https://doi.org/10.26481/dis.20140923rj)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy


If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Chapter 7

Summary



Cell-based therapy for hypoxic-ischemic injury in the preterm brain

Introduction

Preterm infants are prone to hypoxic-ischemic encephalopathy. Unfortunately, no therapy exists to treat this brain injury. The objective of this translational research project was (1) to study the role of the cerebral and peripheral inflammatory response in the etiology of preterm brain injury following global hypoxia-ischemia, and (2) to assess the neuroprotective effect of exogenous administration of stem cells and the mobilization of endogenous stem cells in the preterm brain after global hypoxia-ischemia.

Methods

Instrumented preterm sheep were subjected to global hypoxia-ischemia by 25 minutes of umbilical cord occlusion at a gestational age of 104 (term is 150) days (\pm 32 weeks of human gestation). One hour after global hypoxia-ischemia animals were either treated with (1) exogenous mesenchymal stem cells (MSCs) or (2) mobilization of endogenous stem cells using granulocyte-colony stimulating factor (G-CSF). The study consisted of the treatment groups with appropriate control groups. During a 7 day reperfusion period, all vital parameters, including (amplitude-integrated) electroencephalogram, were recorded. At the end of the experiment, the preterm brain was assessed using histology and diffusion tensor imaging (DTI). The effect of MSCs on the peripheral immune system was assessed in a splenocyte proliferation assay.

Results

Our findings showed that global hypoxia-ischemia induced marked activation and proliferation of microglia in the preterm brain. Furthermore, we observed mobilization of immune effector cells (T-cells and neutrophils), most likely originating from the spleen, that invaded the preterm brain. These pro-inflammatory changes were associated with loss of pre-oligodendrocytes and hypomyelination. Moreover, global hypoxia-ischemia caused persistent suppression of brain activity and a pronounced increase in the number of seizures.

Administration of exogenous mesenchymal stem cells (MSCs) reduced cerebral inflammation and white matter injury. MSCs induced T-cell tolerance, which was paralleled with diminished mobilization and invasion of these cells in the preterm brain. In addition, MSCs established functional improvement, as shown by decreased number of seizures after global hypoxia-ischemia.

Similarly, mobilization of endogenous stem cells using systemic granulocyte-colony stimulating factor (G-CSF) reduced cerebral inflammation and white matter injury. However, G-CSF did not reduce the number of seizures after global hypoxia-ischemia.

Conclusion

We have shown in a translational animal model that cell-based therapy is effective in protecting the preterm brain against the cerebral and peripheral inflammatory responses that are involved in the etiology of white matter injury in the preterm brain after global hypoxia-ischemia. Our findings indicated that the administration of exogenous MSCs in particular is an effective method to reduce hypoxic-ischemic injury in the preterm brain. Our studies form the basis for future clinical trials, which will study feasibility of cell-based therapy in preterm infants with hypoxic-ischemic encephalopathy, creating an eligible chance to improve the life of many preterm infants that suffer from hypoxic-ischemic brain injury.